Answers are grounded in this paper and cite their sources.
Introduction: Over the past years, we have witnessed the discovery of several oncogenic driver mutations, and the emergence of specific inhibitors with high response rates and few treatment-related adverse events. RET-rearranged lung cancers represent a small subset of lung cancers, most commonly encountered in patients with adenocarcinoma and minimal or no exposure to tobacco. Several multikinase inhibitors have been tested with high ‘off-target’ toxicity and low RET inhibition activity.Areas covered: Here, we review the main aspects of the biology of RET, the challenges of RET inhibition in lung cancers, clinical data from several multikinase inhibitors, and some future perspectives with regard to precision oncology.Expert commentary: Early phase clinical trials results of more selective RET inhibitors are eagerly awaited.
No takes yet. Share an insight, caveat, or question.
Fernando C. Santini (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: